Premium
P3‐268: THE A/T/N CLASSIFICATION IN THE PROGNOSIS OF MILD COGNITIVE IMPAIRMENT IN THE ARGENTINE‐ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE COHORT
Author(s) -
Pertierra Lucia,
Chrem Mendez Patricio Alexis,
Russo Maria Julieta,
Cohen Gabriela,
Calandri Ismael Luis,
Campos Jorge,
Nahas Federico,
Surace Ezequiel,
Vazquez Silvia,
Sevlever Gustavo,
Ricardo Allegri F.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1628
Subject(s) - biomarker , dementia , cohort , alzheimer's disease neuroimaging initiative , neuroimaging , oncology , medicine , disease , neurodegeneration , cognitive impairment , psychology , psychiatry , biology , biochemistry
patients were classified based on their baseline CSF biomarker levels as biomarker (BM)-positive or BM-negative. Clinical decline was determined by following the patients over a period of 24 months, based on Mini-Mental State Examination (MMSE) and Clinical Dementia Rating-Sum of Boxes (CDR-SB) and Functional Activities Questionnaire (FAQ) scores. The ability of the CSF biomarkers and ratios to separate patients with higher versus lower change in clinical scores was estimated based on a multivariable linear mixed effects model. Time-to-event analyses, including Kaplan-Meier curves, were performed for outcome dementia (follow-up of up to 72 months). Results:MMSE scores showed a significantly stronger decrease in BM-positive compared with BM-negative patients (Table 1, Figure 1). pTau/Ab42 and tTau/ Ab42 ratios performed better as predictors of clinical decline than single biomarkers (Table 1). Similar results were obtained for the other scores (Table 1). Although no clear optimum for the biomarker cut-offs could be identified, good separation was observed between patients with lower and higher risk of progression to dementia for the biomarkers (Figure 2). Conclusions: